Eli Lilly unveiled the first batch of clinical data from its investigational next-generation FR-targeted ADC in platinum-sensitive ovarian cancer at the 2026 ESMO conference.

Zhitongcaijing · 2d ago
Eli Lilly unveiled the first batch of clinical data from its investigational next-generation FR-targeted ADC in platinum-sensitive ovarian cancer at the 2026 ESMO conference.